stockportfolio.pro
Stocks / IART vs MAZE
IART vs MAZE
Integra LifeSciences Holdings Corporation and Maze Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Integra LifeSciences Holdings Corporation (IART) | Maze Therapeutics, Inc. (MAZE) | |
|---|---|---|
| Market cap | $1.3B | $1.4B |
| Revenue (latest FY) | $1.64B | $0 |
| Net income (latest FY) | $-516.47M | $-131.12M |
| Revenue growth (5y CAGR) | 3.6% | — |
| Net margin | -31.6% | — |
| Return on equity | -49.5% | -36.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 8 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IART — free Open MAZE — freeFrequently asked questions
Which is bigger, IART or MAZE?
Maze Therapeutics, Inc. is larger by market capitalization — $1.4B versus $1.3B.
Which grows faster, IART or MAZE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.